Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Cannon, Christopher P. [VerfasserIn]   i
 Harrington, Robert A [VerfasserIn]   i
 James, Stefan [VerfasserIn]   i
 Ardissino, Diego [VerfasserIn]   i
 Becker, Richard C [VerfasserIn]   i
 Emanuelsson, Håkan [VerfasserIn]   i
 Husted, Steen [VerfasserIn]   i
 Katus, Hugo [VerfasserIn]   i
 Keltai, Matyas [VerfasserIn]   i
 Khurmi, Nardev S [VerfasserIn]   i
 Kontny, Frederic [VerfasserIn]   i
 Lewis, Basil S [VerfasserIn]   i
 Steg, Philippe Gabriel [VerfasserIn]   i
 Storey, Robert F [VerfasserIn]   i
 Wojdyla, Daniel [VerfasserIn]   i
 Wallentin, Lars [VerfasserIn]   i
Titel:Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO)
Titelzusatz:a randomised double-blind study
Verf.angabe:Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin for the PLATelet inhibition and patient Outcomes (PLATO) investigators
E-Jahr:2010
Jahr:13 January 2010
Umfang:11 S.
Fussnoten:Gesehen am 29.03.2023
Titel Quelle:Enthalten in: The lancet <London>
Ort Quelle:London [u.a.] : Elsevier, 1823
Jahr Quelle:2010
Band/Heft Quelle:375(2010), 9711, Seite 283-293
ISSN Quelle:1474-547X
Abstract:Background - Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes. We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patients. - Methods - At randomisation, an invasive strategy was planned for 13 408 (72·0%) of 18 624 patients hospitalised for acute coronary syndromes (with or without ST elevation). In a double-blind, double-dummy study, patients were randomly assigned in a one-to-one ratio to ticagrelor and placebo (180 mg loading dose followed by 90 mg twice a day), or to clopidogrel and placebo (300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day) for 6-12 months. All patients were given aspirin. The primary composite endpoint was cardiovascular death, myocardial infarction, or stroke. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00391872. - Findings - 6732 patients were assigned to ticagrelor and 6676 to clopidogrel. The primary composite endpoint occurred in fewer patients in the ticagrelor group than in the clopidogrel group (569 [event rate at 360 days 9·0%] vs 668 [10·7%], hazard ratio 0·84, 95% CI 0·75-0·94; p=0·0025). There was no difference between clopidogrel and ticagrelor groups in the rates of total major bleeding (691 [11·6%] vs 689 [11·5%], 0·99 [0·89-1·10]; p=0·8803) or severe bleeding, as defined according to the Global Use of Strategies To Open occluded coronary arteries, (198 [3·2%] vs 185 [2·9%], 0·91 [0·74-1·12]; p=0·3785). - Interpretation - Ticagrelor seems to be a better option than clopidogrel for patients with acute coronary syndromes for whom an early invasive strategy is planned. - Funding - AstraZeneca.
DOI:doi:10.1016/S0140-6736(09)62191-7
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/S0140-6736(09)62191-7
 Volltext: https://www.sciencedirect.com/science/article/pii/S0140673609621917
 DOI: https://doi.org/10.1016/S0140-6736(09)62191-7
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1840460326
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69057662   QR-Code
zum Seitenanfang